Adaptimmune's enhanced T-cell therapy gets FDA breakthrough status for synovial sarcoma

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for British biopharmaceutical firm Adaptimmune Therapeutics' affinity enhanced T-cell therapy targeting NY-ESO in synovial sarcoma.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news